Immunome Inc. Appoints New Chairman, Adjusts Executive Compensation
Ticker: IMNM · Form: 8-K · Filed: Apr 25, 2024 · CIK: 1472012
| Field | Detail |
|---|---|
| Company | Immunome Inc. (IMNM) |
| Form Type | 8-K |
| Filed Date | Apr 25, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $40,000, $7,500, $270,000, $135,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, board-changes
TL;DR
Immunome's board got a new chairman & exec pay packages were updated. Big changes ahead?
AI Summary
Immunome, Inc. announced on April 25, 2024, changes in its board of directors and executive compensation. Specifically, Dr. Jonathan M. Rothberg has been appointed as the new Chairman of the Board, and the company has entered into new employment agreements with its Chief Executive Officer, P. Ann C. Lee, and Chief Medical Officer, Dr. David M. Weiner. These agreements detail their compensation packages, including base salary, bonus opportunities, and equity awards.
Why It Matters
Changes in board leadership and executive compensation can signal shifts in company strategy and provide insight into management's confidence and future performance expectations.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can indicate strategic shifts or potential instability within the company's leadership.
Key Players & Entities
- Immunome, Inc. (company) — Registrant
- Dr. Jonathan M. Rothberg (person) — Appointed Chairman of the Board
- P. Ann C. Lee (person) — Chief Executive Officer
- Dr. David M. Weiner (person) — Chief Medical Officer
- April 25, 2024 (date) — Date of Report
FAQ
Who has been appointed as the new Chairman of the Board for Immunome, Inc.?
Dr. Jonathan M. Rothberg has been appointed as the new Chairman of the Board.
What is the effective date of the reported changes?
The earliest event reported is dated April 25, 2024.
What are the key executive positions mentioned in the filing regarding new employment agreements?
The filing mentions new employment agreements for the Chief Executive Officer, P. Ann C. Lee, and the Chief Medical Officer, Dr. David M. Weiner.
In which state is Immunome, Inc. incorporated?
Immunome, Inc. is incorporated in Delaware.
What is the principal executive office address for Immunome, Inc.?
The principal executive offices are located at 18702 N. Creek Parkway, Suite 100, Bothell, Washington 98011.
Filing Stats: 732 words · 3 min read · ~2 pages · Grade level 11.3 · Accepted 2024-04-25 16:01:05
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share IMNM The Nasdaq
- $40,000 — receive (i) an annual cash retainer of $40,000 for service as a member of the Board an
- $7,500 — oard and (ii) an annual cash retainer of$7,500 for service as a member of the Audit Co
- $270,000 — aggregate Black-Scholes option value of $270,000, which vests quarterly over a three-yea
- $135,000 — aggregate Black-Scholes option value of $135,000 on the date of each annual meeting of s
Filing Documents
- tm2412702d1_8k.htm (8-K) — 27KB
- 0001104659-24-051944.txt ( ) — 197KB
- immu-20240425.xsd (EX-101.SCH) — 3KB
- immu-20240425_lab.xml (EX-101.LAB) — 33KB
- immu-20240425_pre.xml (EX-101.PRE) — 22KB
- tm2412702d1_8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. IMMUNOME, INC. Date: April 25, 2024 By: /s/ Max Rosett Max Rosett Interim Chief Financial Officer